News Releases

SPARTA, N.J. , Nov. 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs

-- Results demonstrate strong execution of initial phase of VAZALORE commercial launch, including shipments to 30,000+ stores nationwide and e-commerce sites -- -- Reported net revenue of $6.6 million in third quarter 2021 reflecting initial sales of VAZALORE -- -- Third quarter 2021 net loss was (

-- VAZALORE 81 mg shows fast bioavailability, absorption, and platelet inhibition -- -- VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent with VAZALORE 325 mg -- -- Findings presented at TCT meeting earlier today -- SPARTA, N.J. , Nov.

SPARTA, N.J. , Nov. 01, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform that has the potential to improve the absorption of many drugs

-- Supplied VAZALORE to 30,000+ stores nationwide and e-commerce sites -- -- Launch in line with expectations and exceptionally positive feedback from consumers and healthcare professionals received -- -- Third quarter 2021 earnings and business update conference call scheduled for November 12 th

Aspirin remains an established practice for the prevention of another heart attack or clot-related stroke SPARTA, N.J., October 14, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a specialty pharmaceutical company focused on its clinically-validated and

SPARTA, N.J. , Sept. 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead

-- Executing broad reach television advertising to support the launch of VAZALORE -- -- Media campaign reach matches extensive distribution at retailers -- SPARTA, N.J. , Aug. 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company

--Walmart, Walgreens, Rite Aid, CVS and many other retailers placing VAZALORE on shelves later this month-- --VAZALORE launch inventory manufactured and currently shipping to retailers across the country-- SPARTA, N.J. , Aug. 06, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc.

Shelf space for all three SKUs of VAZALORE is reserved with “Coming Soon” shelf placeholders SPARTA, N.J. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected